Insilico Medicine and Atossa Therapeutics Unveil AI-Driven Study Identifying (Z)-Endoxifen as Promising Glioblastoma Therapeutic Candidate

Insilico Medicine and Atossa Therapeutics published a study in Nature Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma. The AI-driven study used Insilico's PandaOmics platform to evaluate the molecule's potential across various cancer types. The study found that endoxifen could counteract pathways associated with tumor growth and treatment resistance, making it a promising candidate for further investigation.